Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden

References

• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.
   PubMed Web of Science ®Google Scholar
• Scher HI, Solo K, Valant J, et al. Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model. PLoS One. 2015;10:112.
   Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–148.
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–433.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–1197.
   PubMed Web of Science ®Google Scholar
• James ND, Spears MR, Clarke NW, et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67:1028–1038.
   PubMed Web of Science ®Google Scholar
• The National Board of Health and Welfare - Socialstyrelsen. Cause of Death n.d [cited 2016 September 26]. Available from: http://www.socialstyrelsen.se/statistics/statisticaldatabase/causeofdeath.
   Google Scholar
• Cherny N, Sullivan R, Torode J, et al. ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe. Ann Oncol. 2016;27:1423–1443.
   PubMed Web of Science ®Google Scholar
• Van Hemelrijck M, Wigertz A, Sandin F, et al. Cohort profile: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int J Epidemiol. 2013;42:956–967.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
   PubMedGoogle Scholar
• Lissbrant IF, Garmo H, Widmark A, et al. Population-based study on use of chemotherapy in men with castration resistant prostate cancer. Acta Oncol. 2013;52:1593–1601.
   PubMed Web of Science ®Google Scholar
• Tomic K, Berglund A, Robinson D, et al. Capture rate and representativity of The National Prostate Cancer Register of Sweden. Acta Oncol. 2015;54:158–163.
   PubMed Web of Science ®Google Scholar
• Tomic K, Sandin F, Wigertz A, et al. Evaluation of data quality in the National Prostate Cancer Register of Sweden. Eur J Cancer. 2015;51:101–111.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983–992.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152–160.
   PubMed Web of Science ®Google Scholar
• Italiano A, Ortholan C, Oudard S, et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol. 2009;55:1368–1375.
   PubMed Web of Science ®Google Scholar
• Smith MR, Rathkopf DE, Mulders PFA, et al. Efficacy and safety of abiraterone acetate in elderly (75 years or older) chemotherapy naive patients with metastatic castration resistant prostate cancer. J Urol. 2015;194:1277–1284.
   PubMed Web of Science ®Google Scholar
• Graff JN, Baciarello G, Armstrong AJ, et al. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann Oncol. 2016;27:286–294.
   PubMed Web of Science ®Google Scholar
• Droz J-P, Aapro M, Balducci L, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol. 2014;15:e404–e414.
   PubMed Web of Science ®Google Scholar
• Yellen SB, Cella DF, Leslie WT. Age and clinical decision making in oncology patients. J Natl Cancer Inst. 1994;86:1766–1770.
   PubMed Web of Science ®Google Scholar
• Schonberg MA, Marcantonio ER, Li D, et al. Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. JCO. 2010;28:2038–2045.
   PubMed Web of Science ®Google Scholar
• Dotan E, Browner I, Hurria A, et al. Challenges in the management of older patients with colon cancer. J Natl Compr Canc Netw. 2012;10:213–224.
   PubMed Web of Science ®Google Scholar
• Anderson J, Van Poppel H, Bellmunt J, et al. Chemotherapy for older patients with prostate cancer. BJU Int. 2007;99:269–273.
   PubMed Web of Science ®Google Scholar
• Jacobs BL, Lopa SH, Yabes JG, et al. Association of functional status and treatment choice among older men with prostate cancer in the Medicare Advantage population. Cancer. 2016;122:3199–3206.
   PubMed Web of Science ®Google Scholar
• Berglund A, Garmo H, Robinson D, et al. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer. Eur J Cancer. 2012;48:75–84.
   PubMed Web of Science ®Google Scholar
• Krupski TL, Kwan L, Afifi AA, et al. Geographic and socioeconomic variation in the treatment of prostate cancer. JCO. 2005;23:7881–7888.
   PubMed Web of Science ®Google Scholar
• Eaker S, Halmin M, Bellocco R, et al. Social differences in breast cancer survival in relation to patient management within a National Health Care System (Sweden). Int J Cancer. 2009;124:180–187.
   PubMed Web of Science ®Google Scholar
• Malangone-Monaco E, Foley K, Varker H, et al. Prescribing patterns of oral antineoplastic therapies observed in the treatment of patients with advanced prostate cancer between 2012 and 2014: results of an oncology EMR analysis. Clin Ther. 2016;38:1817–1824.
   PubMed Web of Science ®Google Scholar